

MetaGuideX

Dr Ryan Pink, CEO
Assoc Professor

Redefining the multi-cancer
care pathway through
innovative diagnostic tests
and therapeutics



The Problem


Cancer often goes **undetected**
leading to **reduced survival**
rates

48% currently diagnosed at **late stage**, only **50%** 10-year survival

90% would survive with early
diagnosis*

The Solution

MetaGuideX blood test
for **multiple early-stage**
cancer types, offering a
new Healthcare tool







Our expertise in Exosomes
make us unique

MetaGuideX Blood Biopsies data so far

costs £33 a test*

Just 1ml of blood



*without overheads

Growing number of treatments for early-stage cancer (approved by FDA since 2020)

Non small cell lung cancer

- Opdivo (nivolumab – PD-1 inhib, BMS) - \$8bn 2022
- Tecentriq (Atezolizumab – PD-1 inhib, Roche) - \$3bn 2021
- Keytruda (Pembrolizumab – PD-1 inhib, Merck) - \$22bn 2022.

Breast Cancer

- 3N - Keytruda (Pembrolizumab – PD-1 inhib, Merck) - \$22bn 2022.
- Verzenio (Abemaciclib-CDK inhibitor, Eli Lilly) - \$4.6bn 2021
- Lynparza (Olaparib-PARP inhibitor, AZ) - \$3bn 2021
- Perjeta (Pertuzumab-HER2, Genentech) - \$5.8bn 2022

Also: Glioma, Leukemia,
Melanoma, Myeloma

Could be part of a bigger piece, but diagnostic is current focus

An early multi-cancer blood diagnostic

Companion diagnostic

Supports new early cancer therapies reach wider market

i.e. Keytruda
(pembrolizumab)
\$22bn rev 2022




A multi-cancer metastatic blocker treatment

90% of patients die of the metastasis rather than the primary tumour

Potential for long term and repeated dose over high risk periods of surgery

MetaGuideX


Blood Biopsies data with more dynamic range
(non-clinical platform – ELISA translation?)



Science & Technology Facilities Council
Rutherford Appleton Laboratory



Innovate
UK




MetaGuideX

Other platforms



heif HIGHER EDUCATION
INNOVATION FUND



Here's a list of some key cfDNA companies:

- Agilent Technologies, Inc.
- Biodesix
- Eurofins Genomics
- F. Hoffmann-La Roche Ltd.
- Illumina, Inc.
- Laboratory Corporation of America Holdings (LabCorp)
- Natera, Inc.
- Quest Diagnostics
- Revvity
- Thermo Fisher Scientific Inc.
- Exact Sciences
- GRAIL
- Myriad Genetic Laboratories
- Horizon Discovery
- Resolution Bioscience
- Veracyte
- Abbott
- C2i Genomics
- Exact Sciences
- Qiagen
- Bio-Rad Laboratories
- Cell Microsystems
- Abcodia
- GEN inCode

Planned markets potential

MetaGuideX

Total Market

60M /yr
~\$9 B/yr

Target Market

*Initial focus: Breast, Lung
and Colon Cancer*

15.6 M/yr investigated *



~\$ 2.38 B/yr **

180M /yr
~\$27 B/yr

All cancers

46.7 M/yr investigated *

~\$ 7 B/yr **



Assay for monitoring Breast,
Lung & Colon

Excess of ~\$7.14 B/yr ***

*2018 UK, EU countries with BC 10k+ cases, North America (IARC, WHO) *10 for est. of those investigated


**Based on every eligible patient being tested at \$150 per test

***Three cancers, based on three annual tests at \$150

Product benefits

MetaGuideX

Patient journey



Reduce 9 in 10
referred
without cancer

Just 5%
increase in
early diagnosis
of 3 cancers
save ~133,269
lives/yr

Pick up cancers
with "hidden"
symptoms *i.e.*
pancreatic

Take pressure
off current
diagnostic
testing
capacity

Competition

Blood based assays

CTC and cfDNA

CellSearch (prostate, breast and colorectal)

Guardant360 (lung), Grail (multi), InVisionFirst (lung)


MetaGuideX

Protein biomarker (\$100-150) rather than expensive and time-consuming genomics (\$1000+)

Potential to license to **existing platforms**

Many cancer types with the same assay

Blood exosomes offer a cleaner and **more sensitive signal**



The MetaGuideX Team Current clinical?



Dr Ryan Pink
CEO/Co-Founder/inventor

- Oxford healthcare org boards
- Early cancer diagnosis tech
- Senior Lecturer in Genomics



Dr Soozana Puvanenthiran
R&D

Cancer Biomarkers PhD and
TED speaker



Dr Mark Beggs - COO
CEO UKBiocentre, CE Stratified
Medicine Scotland, Pfizer, Janssen,
AstraZeneca and GSK



Dr David Browning
Chair
ICR, CEO Oxford Cancer
Biomarkers, Amersham
International J&J, Philips, NHS,
OBNI Chair

We have dialogue with:



Prof Dave Carter
Co-Founder/inventor/SAB

- UK Exosome Society President
- Snr Research dir. at Evox
(exosome) Therapeutics



Prof Susan Brooks
Co-Founder/inventor/SAB

- Glycoprotein expert
- Clinical study experience



Prof Nigel Groome
R&D advisor

- Decades of assay and antibody
development
- Patented prenatal testing assays
totalling a billion tests int.



Oxford University Hospitals
NHS Foundation Trust



Rhwydwaith
Cancer Cymru
Wales Cancer
Network



BRIGHAM HEALTH
BRIGHAM AND
WOMEN'S HOSPITAL

MetaGuideX Business Model


Phase 2: Clinical Validation

Phase 3: Regulation


Phase 4: Revenue

(Series A)

(Series B)



Fundraising and aims



Seeking **seed investment** to raise value for series A:

- Clinical validation of 100s Breast/lung/colon Cancer samples
- **Establish on a clinical platform**
- Identify further cancer types (partly non-dilute funded)
- Clinical support and Health economic case
- Regulatory planning
- IP strategy

SEIS
assured

*Non-diluting **convertible loan